John Brassil (Kerry, Fianna Fail) | Oireachtas source

I thank our guests for attending. I seek clarification from Professor Barry to begin. He referred to two specific drugs, namely, Kuvan and Spinraza. He said that following two recent meetings, he recommended to the HSE drug group that access to Kuvan be considered under a managed access programme, with a starting, stopping criteria which I am sure will delight the PKU society. The recommendation on Spinraza is expected shortly. Why is the Spinraza recommendation not public? If Professor Barry can tell us about Kuvan, why can he not tell us about Spinraza?